Excerpt: “Drug manufacturers can’t catch a break, but are they the real culprit?
Sure, we could shake our finger at Heather Bresch, CEO of Mylan, but didn’t we just do this to Martin Shkreli from Turing Pharmaceuticals and Michael Pearson from Valeant? The key question isn’t who’s the offender du jour? Instead, it’s why do these pricing ‘scandals’ keep happening, and is our best offensive strategy public shaming?
Complaining about Mylan is pointless because as a publicly traded company, they’re doing exactly what we would expect to meet the profit and growth expectations of their investors. Why is it their responsibility to compete against themselves? If this were the financial services industry, Bresch would be hailed as a genius.”